

PTO/SB/05B (01-08)

Approved for use through 04/30/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of

5

Complete if Known

Application Number	10/563,189
Filing Date	December 30, 2005
First Named Inventor	Henry Daniell
Art Unit	1638
Examiner Name	Anne R. Kubelik
Attorney Docket Number	10669-039

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R21	PETERSON, C. E. et al. "A dynamic model for bilirubin binding to human serum albumin", J. Biol. Chem., pp. 20985-20995, Vol. 275.	
	R22	PETRIDES, D et al. "Computer-aided process analysis and economic evaluation of for biosynthetic human insulin production" Biotechnology and Bioengineering, 1995, pp. 529-554, Vol. 48, No. 1. (Abstract)	
	R23	QUIRK, A. V. et al. "Production of recombinant human serum albumin from <i>Saccharomyces cerevisiae</i> ", Biotechnol. Appl. Biochem., 1998, pp. 273-287, Vol. 11. (Abstract)	
	R24	ROZKOV, A. et al. "Dynamics of proteolysis and its influence on the accumulation of intracellular recombinant proteins", Enzyme Microbiol. Technol., 2000, pp. 743-748, Vol. 27.	
	R25	RUF, S. et al. "Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit", Nat. Biotechnol., 2001, pp. 870-875, Vol. 19.	
	R26	SAUNDERS, C. W., et al. "Secretion of human serum albumin from <i>Bacillus subtilis</i> ", J. Bacteriol., 1987, pp. 2917-2925, Vol. 169.	
	R27	SHIVELY, J. M., et al. "The carboxysome, a prokaryotic organelle" A mini review", Can. J. Bot., 1991, pp. 957-962, Vol. 69.	
	R28	STAUB, J. M. et al. "High-yield production of a human therapeutic protein in tobacco chloroplasts" Nature Biotechnology, March 2000, pp. 333-338, Vol. 18.	
	R29	STAUB, J. M. et al. "Accumulation of D1 polypeptide in tobacco plastid is regulated via the untranslated region of the psbA mRNA", EMBO J., pp. 601-606, Vol. 12.	
	R30	STAUB, J. M. et al. "Translation of psbA mRNA is regulated by light via the 5'untranslated region in tobacco plastid", Plant, 1994, pp. 547-553, Vol. 6.	

Examiner Signature	/Anne Kubelik/	Date Considered	09/29/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.K./

PTO/SB/08B (01-08)
Approved for use through 04/30/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/563,189
Filing Date	December 30, 2005
First Named Inventor	Henry Daniell
Art Unit	1638
Examiner Name	Anne R. Kubelik
Attorney Docket Number	10669-039

Sheet 4 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R31	TARELLI, E. et al. Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents", <i>Biologicals</i> , pp. 231-246, Vol. 26	
	R32	WATANABE, H., et al. "Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants", <i>Biochem. J.</i> , 2001, pp. 269-274, Vol. 357.	
	R33	WATANABE, H., et al. "In vitro and in vivo properties of recombinant human serum albumin from <i>Pichia pastoris</i> purified by a method of short processing time", 2001 <i>Pharm. Res.</i> , pp. 1775-1781, Vol. 18.	
	R34	ZERGES, W. "Translation in chloroplasts", <i>Biochimie</i> , pp. 583-601, Vol. 82.	
	R35	Daniell, H. "Containment of Herbicide Resistance Through Genetic Engineering of the Chloroplast Genome", <i>Nature Biotech.</i> , 1998, pp. 345-348, Vol. 16.	
	R36		
	R37		
	R38		
	R39		
	R40		

Examiner Signature	/Anne Kubelik/	Date Considered	09/29/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.K./

PTO/SB/ORA (01-08)

Approved for use through 04/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	5	of	5
-------	---	----	---

Complete if Known

Application Number	10/563,189
Filing Date	December 30, 2005
First Named Inventor	Henry Daniel
Art Unit	1638
Examiner Name	Anne R. Kubelik
Attorney Docket Number	10669-039

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

²EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant. ³Applicant's unique citation designation number (optional). ⁴See Kinds Codes of the WIPO Patent Documents at www.wipo.org or MPEP 901.04. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁷Kind of document to be translated. ⁸Indicate the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁹Applicant is to place a check mark here if English language translation is attached.

Translational is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments including the estimated time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.K./